What is NexCure?
NexCure is at the forefront of revolutionizing CAR-T and other advanced treatment delivery. The company specializes in translating hospital-grade clinical rigor into scalable, community-based outpatient clinics. Its innovative platform leverages AI-powered patient selection, sophisticated remote monitoring, and standardized clinical protocols to ensure safe, compassionate, and personalized treatment for every patient. By redesigning the therapeutic delivery model, NexCure aims to make advanced treatments more accessible and efficient.
How much funding has NexCure raised?
NexCure has raised a total of $19M across 1 funding round:
Series A
$19M
Series A (2026): $19M with participation from Oncology Ventures, RA Capital Management, and Cencora
Key Investors in NexCure
Oncology Ventures
Oncology Ventures is dedicated to investing in healthcare data companies that address significant challenges in cancer care, focusing on early detection, patient navigation, and AI-powered treatment optimization.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
Cencora
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere, established in 2023.
What's next for NexCure?
The recent major strategic investment signals a new phase of growth and scaling for NexCure. This capital infusion is expected to accelerate the expansion of its outpatient clinic network and further enhance its technology platform, particularly its AI capabilities for patient selection and remote monitoring. The company is well-positioned to solidify its market leadership in community-based advanced therapeutics, potentially paving the way for further enterprise-level funding rounds as it continues to demonstrate success in its mission to broaden access to life-changing treatments.
See full NexCure company page
